SRF Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 4/6
SRFDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -2.8% zurückgegangen, während in der Branche Chemicals die Gewinne wachsen. Die Umsatzerlöse sind gewachsen mit einer durchschnittlichen Rate von 7.5% pro Jahr. SRF Die Eigenkapitalrendite des Unternehmens beträgt 13.1%, und die Nettomargen liegen bei 11.6%.
Wichtige Informationen
-2.82%
Wachstumsrate der Gewinne
-2.98%
EPS-Wachstumsrate
| Chemicals Wachstum der Industrie | 17.68% |
| Wachstumsrate der Einnahmen | 7.54% |
| Eigenkapitalrendite | 13.07% |
| Netto-Marge | 11.63% |
| Letzte Ertragsaktualisierung | 31 Mar 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrativ-Update • May 22
503806: Expanded Capital Outlay And Dividend Potential Will Support Future Upside
Analysts have trimmed their fair value estimate for SRF from about ₹3,155.83 to ₹2,990.35, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Board meeting scheduled for May 5, 2026, to consider and approve audited financial results for the quarter and year ended March 31, 2026 (company filing).
Narrativ-Update • Apr 30
503806: Future P/E Compression Will Likely Cap Upside Despite Margin Support
The analyst price target for SRF has been adjusted from ₹2,249.74 to ₹2,200.00 as analysts factor in updated assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News SRF has scheduled a board meeting on May 05, 2026 to consider and approve the audited financial results for the quarter and year ended March 31, 2026 (company filing).Narrativ-Update • Apr 08
503806: Fair View As Higher Margins Offset Lower Future P/E Multiple
Analysts have raised their fair value estimate for SRF slightly, from ₹2,239.45 to ₹2,249.74. This reflects updated assumptions for revenue growth, profit margins, a lower assumed discount rate, and a reduced future P/E multiple.Narrativ-Update • Mar 24
503806: Elevated P E And Margins Will Likely Restrain Future Returns
Analysts have modestly increased their fair value estimate for SRF from ₹2,218.36 to ₹2,239.45, citing updated assumptions regarding revenue growth, profit margins, the discount rate, and future P/E, which together support a slightly higher price target. What's in the News SRF's board approved the appointment of Mr. Samir Kashyap as Chief Financial Officer, effective January 27, 2026.Narrativ-Update • Mar 09
503806: Elevated P E And Modest Margins Will Likely Restrain Future Returns
Analysts now set their fair value estimate for SRF at ₹2,218, compared with the previous ₹2,244. This reflects updated assumptions around discount rate, revenue growth, profit margins and future P/E expectations.Narrativ-Update • Feb 23
503806: Elevated P E And Modest Margin Outlook Will Likely Pressure Returns
Analysts have slightly raised their price target on SRF to ₹2,244, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E. These changes keep their fair value view broadly unchanged in headline terms but reflect a modestly adjusted risk and earnings profile.Narrativ-Update • Feb 09
503806: Lower Margins And Rich P E Will Likely Pressure Returns
Analysts have raised their price target on SRF to ₹2,244 from ₹2,213, citing updated assumptions on the discount rate, revenue growth, profit margins and a higher future P/E multiple. What's in the News The board has approved the appointment of Mr. Samir Kashyap as Chief Financial Officer, effective January 27, 2026.Narrativ-Update • Jan 24
503806: New Pharma Plant And CFO Appointment Will Support Future Upside
Analysts have trimmed their price target on SRF to ₹3,155.83 from ₹3,183.00, reflecting slightly more conservative assumptions on revenue growth, profit margin and future P/E, as well as a marginally higher discount rate. What's in the News Board meeting on January 20, 2026 to review unaudited financial results for the quarter and nine months ended December 31, 2025, consider a new pharma intermediate plant project, and discuss a second interim dividend for FY 2025-26 (company filing).
Narrativ-Update • Jan 10
503806: Future Capacity Expansion And CFO Transition Will Support Long Term Prospects
Analysts have kept their fair value estimate for SRF steady at ₹3,841, with only small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that feed into the updated target. This signals broadly consistent expectations compared with prior research.Narrativ-Update • Dec 26
503806: Future Specialty Fluoropolymer Capacity Expansion May Support Long Term Profitability
Analysts have modestly raised their price target on SRF to a new level, in line with incremental improvements in projected revenue growth, profit margins, and a slightly lower future valuation multiple, signaling a cautiously stronger outlook for the stock. What's in the News Chief Financial Officer Rahul Jain will step down from his role at the close of business on 12 December 2025, with SRF initiating the process to identify a successor and ensure a smooth transition (Key Developments).Narrativ-Update • Dec 12
503806: Lower Discount Rate May Support Stronger Long Term Profitability
Analysts have raised their fair value estimate for SRF by approximately $191 to $3,841 per share, citing a modestly lower discount rate and slightly higher long term profit margin expectations that more than offset a small reduction in projected revenue growth. What's in the News Chief Financial Officer Rahul Jain will step down from his role at the close of business on 12 December 2025.Narrativ-Update • Nov 27
503806: CFO Transition And New Facility Approval Will Drive Upside Ahead
Analysts have adjusted their price target for SRF slightly upward from $3,182.93 to $3,183.00, citing minor changes in underlying financial assumptions such as discount rate and projected margin. What's in the News Chief Financial Officer Rahul Jain will step down at the close of business on December 12, 2025.Narrativ-Update • Nov 12
503806: Upcoming CFO Departure And Facility Decision Will Shape Outlook
Analysts have raised their price target for SRF from $3,138.07 to $3,182.93, citing updated forecasts that reflect slight adjustments in growth and profitability assumptions. What's in the News SRF Limited's Chief Financial Officer, Rahul Jain, announced he will step down from his position at the close of business on December 12, 2025.Narrativ-Update • Oct 29
New Facility And Supply Chain Moves Will Drive Balanced Opportunity Ahead
Analysts have slightly raised their price target for SRF from $3,137.83 to $3,138.07, citing improved profit margin projections as well as a modest increase in anticipated revenue growth. What's in the News SRF Limited will hold a Board Meeting on October 27, 2025, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025.Narrativ-Update • Oct 15
Sustainability And Capacity Upgrades Will Transform Specialty Chemicals
Analysts have increased their price target for SRF from $3,104.79 to $3,137.83, reflecting updated expectations for the company's financial outlook. What's in the News The Chemours Company and SRF Limited have signed strategic agreements to enhance the global supply chain for fluoropolymers and fluoroelastomers (Key Developments).Narrativ-Update • Sep 05
Sustainability And Capacity Upgrades Will Transform Specialty Chemicals
With no meaningful change in either the discount rate or forward P/E multiple, analysts have maintained SRF's fair value estimate at ₹3105. What's in the News SRF Limited has entered into strategic agreements with The Chemours Company to strengthen Chemours' global supply chain for fluoropolymers and fluoroelastomers, leveraging SRF's manufacturing capabilities.
Neues Narrativ • Nov 28
Specialty Chemicals Innovations And Global Demand Empower Revenue Growth Journey
SRF's Specialty Chemicals growth and increased production should drive revenue and improve margins due to new product launches and efficiency gains.Aufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie SRF Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 157,865 | 18,352 | 11,483 | 0 |
| 31 Dec 25 | 154,847 | 17,792 | 11,548 | 0 |
| 30 Sep 25 | 152,635 | 16,176 | 11,347 | 0 |
| 30 Jun 25 | 150,476 | 14,309 | 11,110 | 0 |
| 31 Mar 25 | 146,931 | 12,508 | 10,859 | 0 |
| 31 Dec 24 | 139,495 | 11,469 | 10,547 | 0 |
| 30 Sep 24 | 135,112 | 11,293 | 10,378 | 0 |
| 30 Jun 24 | 132,643 | 12,286 | 10,110 | 0 |
| 31 Mar 24 | 131,385 | 13,357 | 9,768 | 0 |
| 31 Dec 23 | 133,469 | 14,760 | 9,422 | 0 |
| 30 Sep 23 | 137,635 | 17,334 | 9,086 | 0 |
| 30 Jun 23 | 143,139 | 19,136 | 8,772 | 0 |
| 31 Mar 23 | 148,703 | 21,623 | 8,535 | 0 |
| 31 Dec 22 | 146,416 | 22,055 | 8,435 | 0 |
| 30 Sep 22 | 145,178 | 22,002 | 8,401 | 0 |
| 30 Jun 22 | 136,290 | 21,016 | 8,226 | 0 |
| 31 Mar 22 | 124,337 | 18,889 | 8,104 | 0 |
| 31 Dec 21 | 114,919 | 16,647 | 7,597 | 0 |
| 30 Sep 21 | 102,924 | 14,834 | 7,108 | 0 |
| 30 Jun 21 | 95,543 | 14,167 | 6,659 | 0 |
| 31 Mar 21 | 84,000 | 11,983 | 6,393 | 0 |
| 31 Dec 20 | 76,502 | 10,110 | 6,079 | 0 |
| 30 Sep 20 | 73,543 | 10,322 | 5,868 | 0 |
| 30 Jun 20 | 69,913 | 9,174 | 5,652 | 0 |
| 31 Mar 20 | 72,094 | 9,159 | 5,567 | 0 |
| 31 Dec 19 | 78,817 | 9,511 | 6,060 | 0 |
| 30 Sep 19 | 78,411 | 7,592 | 5,862 | 0 |
| 30 Jun 19 | 71,216 | 6,331 | 4,993 | 0 |
| 31 Mar 19 | 70,996 | 5,916 | 4,901 | 0 |
| 31 Dec 18 | 72,329 | 5,747 | 5,306 | 0 |
| 30 Sep 18 | 66,660 | 5,402 | 5,199 | 0 |
| 30 Jun 18 | 60,370 | 4,917 | 4,777 | 0 |
| 31 Mar 18 | 55,890 | 4,617 | 5,035 | 0 |
| 31 Dec 17 | 53,026 | 4,670 | 4,951 | 0 |
| 30 Sep 17 | 50,385 | 4,442 | 4,827 | 0 |
| 30 Jun 17 | 48,952 | 4,642 | 4,465 | 0 |
| 31 Mar 17 | 48,218 | 5,150 | 4,585 | 0 |
| 31 Dec 16 | 45,833 | 4,787 | 4,491 | 0 |
| 30 Sep 16 | 45,459 | 4,709 | 4,363 | 0 |
| 30 Jun 16 | 45,980 | 4,537 | 4,016 | 0 |
| 31 Mar 16 | 45,927 | 4,299 | 4,094 | 0 |
| 31 Dec 15 | 45,353 | 3,746 | 5,788 | 0 |
| 30 Sep 15 | 45,511 | 3,453 | 5,722 | 0 |
| 30 Jun 15 | 45,759 | 3,235 | 5,701 | 0 |
Qualität der Erträge: 503806 hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: 503806Die aktuellen Gewinnspannen (11.6%) sind höher als im letzten Jahr (8.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 503806Die Erträge des Unternehmens sind in den letzten 5 Jahren um 2.8% pro Jahr zurückgegangen.
Beschleunigtes Wachstum: 503806Das Gewinnwachstum des Unternehmens im letzten Jahr (46.7%) übertrifft seinen 5-Jahres-Durchschnitt (-2.8% pro Jahr).
Erträge im Vergleich zur Industrie: 503806 Das Gewinnwachstum im vergangenen Jahr (46.7%) übertraf das der Branche Chemicals 11% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 503806Die Eigenkapitalrendite des Unternehmens (13.1%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/26 19:30 |
| Aktienkurs zum Tagesende | 2026/05/26 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
SRF Limited wird von 42 Analysten beobachtet. 31 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Kumar Saumya Singh | Ambit Capital |
| Nitin Bhasin | Ambit Capital |